Sunburst Financial Group LLC Has $225,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Sunburst Financial Group LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 12.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,112 shares of the biopharmaceutical company’s stock after selling 1,127 shares during the quarter. Sunburst Financial Group LLC’s holdings in Pfizer were worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in Pfizer during the 4th quarter worth about $32,000. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in Pfizer during the 4th quarter worth about $37,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday. Morgan Stanley upped their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Stock Up 0.4 %

NYSE:PFE traded up $0.12 during trading hours on Friday, reaching $27.92. 5,644,958 shares of the stock were exchanged, compared to its average volume of 40,686,793. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The firm has a 50 day moving average of $27.81 and a 200 day moving average of $27.69. The stock has a market cap of $158.21 billion, a PE ratio of -467.09, a PEG ratio of 1.08 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 EPS. The business’s revenue was down 19.5% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.02%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.